share_log

南京证券股份有限公司关于江苏诺泰澳赛诺生物制药股份有限公司2023年度持续督导报告书

Nanjing Securities Co., Ltd.'s 2023 continuous supervision report on Jiangsu Nuotai Aosainuo Biopharmaceutical Co., Ltd.

Sensex a share ·  Apr 3
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more